Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin lymphoma, adult
City:  Cleveland
State:  Ohio
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 28 for your search:
Start Over
Double Cord Versus Haploidentical (BMT CTN 1101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 5U24CA076518, 715, NCT01597778
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTMX-M-072-001, NCI-2017-00275, NCT03013491
Lenalidomide, Ixazomib Citrate, and Rituximab in Treating Patients with High Risk, Previously Untreated, Indolent Stage II-IV B-Cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE1414, NCI-2017-00369, NCT02898259
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-009, NCI-2014-02149, NCT02227251
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KTE-C19-102, NCI-2015-02028, NCT02601313
Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Mature T Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE1415, NCI-2016-00018, NCT02588651
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: GS-US-406-1840, NCI-2016-00628, 2015-004572-30, NCT02701634
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: Any age
Trial IDs: BMTCTN1501, NCI-2016-00996, 2U10HL069294-11, 5U24CA076518, NCT02806947
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SGN19A-004, NCI-2016-01454, NCT02855359
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 6637-01, NCI-2016-01676, NCT01656603
Decitabine and Tetrahydrouridine in Treating Patients with Refractory and Relapsed T- or B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE1416, NCI-2016-01902, NCT02846935
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: I137-101, NCI-2013-01211, NCT01905228
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1312, NCI-2013-01368, NCT01925131
ALT-803 in Treating Patients with Advanced Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: CITN-06-ALT-803, NCI-2013-01999, CA-ALT-803-01-13, NCT01946789
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan before Donor Progenitor Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: CASE9Z13, NCI-2014-00837, NCT02129582
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC-486-CAGEN-001, NCI-2015-00973, NCT02223052
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KX02-01-13, NCI-2015-00135, NCT02326441
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ADCT-402-101, NCI-2016-00145, NCT02669017
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN19B-001, NCI-2016-00414, NCT02702141
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: C34005, NCI-2016-01823, 2016-001426-34, U1111-1188-0891, NCT02954406
Start Over